Serina Therapeutics, Inc. Research and Development Expense
Serina Therapeutics, Inc. (SER) reported Research and Development Expense of $3.82 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Serina Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.82M, a 21.07% increase year-over-year.
- Serina Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $3.20M, a 8.40% increase year-over-year.
- Serina Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $3.40M, a 43.81% increase year-over-year.
- Serina Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $3.65M, a 51.18% increase year-over-year.
- Serina Therapeutics, Inc. research and development expense for fiscal 2025 was $13.15M, a 75.87% increase from fiscal 2024.
- Serina Therapeutics, Inc. research and development expense for fiscal 2024 was $7.48M, a 213.23% increase from fiscal 2023.
- Serina Therapeutics, Inc. research and development expense for fiscal 2023 was $2.39M, a 132.98% increase from fiscal 2022.
- Serina Therapeutics, Inc. research and development expense for fiscal 2022 was $1.02M, a 29.60% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.82M 10-Q · filed 2026-08-13 | $7.01M 10-Q · filed 2026-08-13 | $10.42M derived: sum of 3 quarters · filed 2026-08-13 | $14.07M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $3.20M 10-Q · filed 2026-05-14 | $6.60M derived: sum of 2 quarters · filed 2026-05-14 | $10.25M derived: sum of 3 quarters · filed 2026-05-14 | $13.40M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $7.05M derived: sum of 2 quarters · filed 2026-03-25 | $10.20M derived: sum of 3 quarters · filed 2026-08-13 | $13.15M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $3.65M 10-Q · filed 2025-11-13 | $6.80M derived: sum of 2 quarters · filed 2026-08-13 | $9.75M 10-Q · filed 2025-11-13 | $12.12M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $3.15M 10-Q · filed 2026-08-13 | $6.10M 10-Q · filed 2026-08-13 | $8.47M derived: sum of 3 quarters · filed 2026-08-13 | $10.88M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $2.95M 10-Q · filed 2026-05-14 | $5.32M derived: sum of 2 quarters · filed 2026-05-14 | $7.73M derived: sum of 3 quarters · filed 2026-05-14 | $9.32M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.78M derived: sum of 2 quarters · filed 2026-03-25 | $6.37M derived: sum of 3 quarters · filed 2026-03-25 | $7.48M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $2.42M 10-Q · filed 2025-11-13 | $4.01M derived: sum of 2 quarters · filed 2025-11-13 | $5.12M 10-Q · filed 2025-11-13 | $6.02M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.59M 10-Q · filed 2025-08-11 | $2.70M 10-Q · filed 2025-08-11 | $3.61M derived: sum of 3 quarters · filed 2025-08-11 | $4.21M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-08 | $2.01M derived: sum of 2 quarters · filed 2025-05-08 | $2.62M derived: sum of 3 quarters · filed 2025-05-08 | $3.10M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $907.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.51M derived: sum of 2 quarters · filed 2025-03-24 | $1.99M derived: sum of 3 quarters · filed 2025-03-24 | $2.39M 10-K · filed 2025-03-24 | $734.00K 10-K · filed 2024-03-22 | |||
| 2023-09-30 | $603.00K 10-Q · filed 2024-11-12 | $218.00K 10-Q · filed 2023-11-14 | $1.08M derived: sum of 2 quarters · filed 2024-11-12 | $1.48M 10-Q · filed 2024-11-12 | $552.00K 10-Q · filed 2023-11-14 | $1.69M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $479.00K 10-Q · filed 2024-08-09 | $160.00K 10-Q · filed 2023-08-14 | $878.00K 10-Q · filed 2024-08-09 | $334.00K 10-Q · filed 2023-08-14 | $1.09M derived: sum of 3 quarters · filed 2024-08-09 | $1.25M derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | $399.00K 10-Q · filed 2024-05-14 | $174.00K 10-Q · filed 2023-05-12 | $607.00K derived: sum of 2 quarters · filed 2024-05-14 | $769.00K derived: sum of 3 quarters · filed 2024-05-14 | $1.03M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $208.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $370.00K derived: sum of 2 quarters · filed 2024-03-22 | $629.00K derived: sum of 3 quarters · filed 2024-03-22 | $1.02M 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | $162.00K 10-Q · filed 2023-11-14 | $421.00K derived: sum of 2 quarters · filed 2023-11-14 | $817.00K 10-Q · filed 2023-11-14 | $1.19M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $259.00K 10-Q · filed 2023-08-14 | $655.00K 10-Q · filed 2023-08-14 | $1.03M derived: sum of 3 quarters · filed 2023-08-14 | $1.31M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $396.00K 10-Q · filed 2023-05-12 | $772.00K derived: sum of 2 quarters · filed 2023-05-12 | $1.05M derived: sum of 3 quarters · filed 2023-05-12 | $1.53M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $651.00K derived: sum of 2 quarters · filed 2023-03-31 | $1.13M derived: sum of 3 quarters · filed 2023-03-31 | $1.46M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $275.00K 10-Q · filed 2022-11-10 | $756.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.08M 10-Q · filed 2022-11-10 | $1.99M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $481.00K 10-Q · filed 2022-08-12 | $805.00K 10-Q · filed 2022-08-12 | $1.71M derived: sum of 3 quarters · filed 2022-08-12 | $2.36M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $324.00K 10-Q · filed 2022-05-13 | $1.23M derived: sum of 2 quarters · filed 2022-05-13 | $1.88M derived: sum of 3 quarters · filed 2022-05-13 | $2.82M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $905.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.56M derived: sum of 2 quarters · filed 2022-03-29 | $2.49M derived: sum of 3 quarters · filed 2022-03-29 | $3.71M 10-K · filed 2022-03-29 | $4.98M 10-K · filed 2021-03-31 | |||
| 2020-09-30 | $653.00K 10-Q · filed 2021-11-12 | $839.00K 10-Q · filed 2020-11-16 | $1.59M derived: sum of 2 quarters · filed 2021-11-12 | $2.81M 10-Q · filed 2021-11-12 | $3.79M 10-Q · filed 2020-11-16 | $4.28M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $935.00K 10-Q · filed 2021-08-13 | $1.35M 10-Q · filed 2020-08-14 | $2.16M 10-Q · filed 2021-08-13 | $2.95M 10-Q · filed 2020-08-14 | $3.63M derived: sum of 3 quarters · filed 2021-08-13 | $5.07M derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $1.22M 10-Q · filed 2021-05-17 | $1.60M 10-Q · filed 2020-05-14 | $2.69M derived: sum of 2 quarters · filed 2021-05-17 | $4.14M derived: sum of 3 quarters · filed 2021-05-17 | $5.79M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $2.92M derived: sum of 2 quarters · filed 2021-03-31 | $4.57M derived: sum of 3 quarters · filed 2021-03-31 | $5.90M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $1.45M 10-Q · filed 2020-11-16 | $3.10M derived: sum of 2 quarters · filed 2020-11-16 | $4.43M 10-Q · filed 2020-11-16 | $5.96M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $1.65M 10-Q · filed 2020-08-14 | $2.99M 10-Q · filed 2020-08-14 | $4.51M derived: sum of 3 quarters · filed 2020-08-14 | $5.84M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $1.34M 10-Q · filed 2020-05-14 | $2.86M derived: sum of 2 quarters · filed 2020-05-14 | $4.19M derived: sum of 3 quarters · filed 2020-05-14 | $5.58M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $1.52M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-03-31 | $2.85M derived: sum of 2 quarters · filed 2020-03-31 | $4.24M derived: sum of 3 quarters · filed 2020-03-31 | $5.83M 10-K/A · filed 2020-03-31 | ||||
| 2018-09-30 | $1.33M 10-Q · filed 2019-11-14 | $2.72M derived: sum of 2 quarters · filed 2019-11-14 | $4.31M 10-Q · filed 2019-11-14 | |||||
| 2018-06-30 | $1.38M 10-Q · filed 2019-08-14 | $2.98M 10-Q · filed 2019-08-14 | ||||||
| 2018-03-31 | $1.59M 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $5.78M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |